India's Cadila to end late-stage trials of potential COVID-19 vaccine in March

By Sumit Khanna

AHMEDABAD, India July 17 (Reuters) - India's Zydus Cadila CADI.NS plans to complete late-stage trials for its potential coronavirus vaccine in March 2021 and could produce up to 100 million doses a year if trials are successful, Chairman Pankaj Patel told Reuters.

Cadila's vaccine candidate, dubbed ZyCov-D, is one of dozens being developed around the world to fight the coronavirus.

(Writing by Zeba Siddiqui; Editing by Edmund Blair)

((; +91-9769624550; @zebatweets; Reuters Messaging:

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.